This inventor holds 4 USPTO granted patents and 6 published patent applications. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2026
Title: Lucas D BonDurant: Innovator in RNAi Therapeutics
Introduction
Lucas D BonDurant is a prominent inventor based in Brookline, MA (US), known for his significant contributions to the field of RNA interference (RNAi) therapeutics. With a total of 4 patents, BonDurant has focused on developing innovative solutions for disorders related to lipid metabolism.
Latest Patents
His latest patents include "Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof," which relates to RNAi agents targeting the ANGPTL3 gene. This invention provides methods for inhibiting the expression of the ANGPTL3 gene and offers potential treatments for ANGPTL3-associated disorders, such as hyperlipidemia and hypertriglyceridemia. Another notable patent is "Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof," which focuses on RNAi agents targeting the APOC3 gene. This invention aims to inhibit the expression of the APOC3 gene and addresses various disorders, including hypertriglyceridemia, non-alcoholic fatty liver disease, and type 2 diabetes mellitus.
Career Highlights
Lucas D BonDurant is currently associated with Alnylam Pharmaceuticals, Inc., a leading company in the development of RNAi therapeutics. His work has been instrumental in advancing the understanding and application of RNAi technology in treating complex diseases.
Collaborations
Throughout his career, BonDurant has collaborated with notable colleagues, including Mark K Schlegel and Jeffrey Zuber, contributing to a dynamic research environment that fosters innovation.
Conclusion
Lucas D BonDurant's work in RNAi therapeutics exemplifies the impact of innovative thinking in addressing significant health challenges. His patents and collaborations continue to pave the way for advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile